How many drugs treat Hypertriglyceridemia?

Drug Landscape tracks 10 marketed treatments for Hypertriglyceridemia (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/hypertriglyceridemia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Hypertriglyceridemia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hypertriglyceridemia (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Hypertriglyceridemia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Epanova	OMEGA-3-CARBOXYLIC ACIDS	AstraZeneca	Omega-3 Fatty Acid		2014-01-01
Vascepa	ICOSAPENT ETHYL	Amarin Pharms	icosapent ethyl	Diacylglycerol O-acyltransferase 1	2012-01-01
Trilipix	CHOLINE FENOFIBRATE	AbbVie	Peroxisome Proliferator Receptor alpha Agonist	Fatty acid-binding protein, intestinal	2008-01-01
Crestor	rosuvastatin	AstraZeneca	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	2003-01-01
Lipitor	atorvastatin	Pfizer Inc.	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	1996-12-17
Lipitor	Atorvastatin Calcium	Pfizer	atorvastatin	3-hydroxy-3-methylglutaryl-coenzyme A reductase	1996-01-01
Tricor (Micronized)	FENOFIBRATE	Salix	Peroxisome Proliferator Receptor alpha Agonist [EPC]	PPARα	1993-01-01
Mevacor	LOVASTATIN	Merck & Co.	HMG-CoA Reductase Inhibitor	3-hydroxy-3-methylglutaryl-coenzyme A reductase	1987-01-01
Lipanor	CIPROFIBRATE	Winthrop Pharmaceuticals UK Limited	ciprofibrate	Peroxisome proliferator-activated receptor alpha	1985-01-01
Lopid	GEMFIBROZIL	Pfizer	Peroxisome Proliferator Receptor alpha Agonist [EPC]	Transthyretin	1981-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

AstraZeneca · 3 drugs in Hypertriglyceridemia
Merck & Co. · 2 drugs in Hypertriglyceridemia
Pfizer · 2 drugs in Hypertriglyceridemia
Pfizer Inc. · 2 drugs in Hypertriglyceridemia
Gachon University Gil Medical Center · 1 drug in Hypertriglyceridemia
MEDPOINTE PHARM HLC · 1 drug in Hypertriglyceridemia
Medpointe Pharm Hlc · 1 drug in Hypertriglyceridemia
Salix · 1 drug in Hypertriglyceridemia
University of Colorado, Denver · 1 drug in Hypertriglyceridemia
University of Louisville · 1 drug in Hypertriglyceridemia
· 1 drug in Hypertriglyceridemia
Winthrop Pharmaceuticals UK Limited · 1 drug in Hypertriglyceridemia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Hypertriglyceridemia:

Cite this brief

Drug Landscape (2026). Hypertriglyceridemia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hypertriglyceridemia. Accessed 2026-06-10.

Hypertriglyceridemia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing